Evidence map›Paper›PMID 41480653›Full record

ReviewDiabetes, obesity & metabolism2026

Challenges in glycaemic control among women with type 1 diabetes and the role of MiniMed 780G system: A narrative review.

Isabeau Thijs, Sarah E Siegelaar, Yasmine I Elhenawy, Katrien Benhalima, Orit Pinhas-Hamiel, Tim van den Heuvel, Javier Castañeda, Ohad Cohen

Abstract readReview
In one paragraph

Review in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Isabeau ThijsMedtronic Diabetes, Medtronic International Trading Sàrl, Tolochenaz, Switzerland.ORCID 0000-0001-5516-4481
Sarah E SiegelaarDepartment of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-6928-8984
Yasmine I ElhenawyPaediatric and Adolescent Diabetes Unit (PADU), Department of Paediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0003-4499-4695
Katrien BenhalimaEndocrinology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.ORCID 0000-0002-3325-0263
Orit Pinhas-HamielSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0001-8365-8091
Tim van den HeuvelMedtronic Diabetes, Medtronic International Trading Sàrl, Tolochenaz, Switzerland.ORCID 0000-0002-3907-6876
Javier CastañedaMedtronic Diabetes, Medtronic International Trading Sàrl, Tolochenaz, Switzerland.ORCID 0000-0003-0752-8847
Ohad CohenMedtronic Diabetes, Medtronic International Trading Sàrl, Tolochenaz, Switzerland.ORCID 0000-0003-4337-1795

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sex-based disparities in the incidence, prevalence and disease manifestations have been observed across various medical conditions, including type 1 diabetes (T1D). Differences in glycaemic control and quality of life between men and women have been reported, with women experiencing lower rates of glycaemic targets and a higher risk for long-term complications, particularly cardiovascular disease. Additionally, women face a greater economic and mental health burden related to T1D. This narrative review explores the challenges that complicate glycaemic management in women living with T1D, including hormonal influences during puberty, pregnancy and the (peri-) menopausal period. We also summarize current available evidence on the safety and efficacy of the MiniMed™ 780G (MM780G) system in addressing these challenges for women living with T1D. Finally, recent real-world data are reported on the absence of significant sex-related differences in glycaemic outcomes of over 280 000 real-world users of the MM780G, across various age groups from childhood and adolescence to the (peri-) menopausal period.

Indexed as

Diabetes Mellitus, Type 1Glycemic ControlHypoglycemic AgentsInsulinInsulin Infusion SystemsAdolescentBlood GlucoseFemaleGlycated HemoglobinHumansPregnancyPregnancy in DiabeticsQuality of LifeBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinautomated insulin deliveryfemalesmenopauseMiniMed™ 780G systempregnancypubertysex disparitiessex hormonestype 1 diabetes

Identifiers

PMID41480653
PMCPMC12805931

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.